SEARCH:   Advanced

Blood, 15 September 2007, Vol. 110, No. 6, pp. 1871-1878. Prepublished online as a Blood First Edition Paper on May 30, 2007; DOI 10.1182/blood-2007-03-081414. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-03-081414v1 110/6/1871    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mancini, F. Articles by Torti, M. Search for Related Content PubMed PubMed Citation Articles by Mancini, F. Articles by Torti, M. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The low-molecular-weight phosphotyrosine phosphatase is a negative regulator of FcRIIA-mediated cell activation Francesca Mancini1, Stefania Rigacci2, Andrea Berti2, Cesare Balduini1, and Mauro Torti1 1 Department of Biochemistry, University of Pavia, Pavia; 2 Department of Biochemical Sciences, University of Florence, Florence, Italy    Abstract Top Abstract Introduction Materials and methods Results Discussion Authorship References   Activation of human platelets by cross-linking of the low-affinity receptor for immunoglobulin G (FcRIIA) is initiated by Src kinase–mediated phosphorylation of the immunoreceptor tyrosine–based activation motif (ITAM) within the receptor, but the identity of the enzyme responsible for its dephosphorylation and inactivation is unknown. Here we report that the 18-kDa low-molecular-weight phosphotyrosine phosphatase (LMW-PTP) is expressed in human platelets and undergoes subcellular redistribution upon FcRIIA cross-linking. In vitro, LMW-PTP was found to efficiently dephosphorylate activated FcRIIA and LAT, but not Syk or phospholipase C2. In the megakaryocytic cell line DAMI, antibody-induced phosphorylation of FcRIIA was rapid and transient. The late dephosphorylation of FcRIIA was dramatically delayed upon reduction of LMW-PTP expression by siRNA. Strikingly, overexpression of LMW-PTP resulted in the inhibition of antibody-induced phosphorylation of FcRIIA, and caused a more rapid dephosphorylation. In addition, overexpression of LMW-PTP inhibited activation of Syk downstream of FcRIIA and reduced intracellular Ca2+ mobilization. These results demonstrate that LMW-PTP is responsible for FcRIIA dephosphorylation, and is implicated in the down-regulation of cell activation mediated by this ITAM-bearing immunoreceptor.    Introduction Top Abstract Introduction Materials and methods Results Discussion Authorship References   The transient phosphorylation of proteins on tyrosine residues represents a very common and versatile signaling mechanism regulating several cellular functions. Changes in the tyrosine phosphorylation level of multiple intracellular substrates also occur in circulating blood platelets upon stimulation with virtually all the physiological agonists.1,2 These include soluble molecules acting on 7 transmembrane G-protein–coupled receptors, such as thrombin or thromboxane A2; adhesive proteins, such as von Willebrand factor (VWF) and collagen, which bind to the peculiar platelet receptors GPIb-IX-V and GPVI, respectively; and integrin ligands, such as fibrinogen, which initiates an outside-in signaling process regulating platelet aggregation and clot retraction.1–5 The overall level of protein tyrosine phosphorylation and the regulation of the strength and duration of a phosphorylation-based signaling pathway result from the balanced action of protein kinases and phosphatases. While a large repertoire of soluble cytosolic tyrosine kinases has been described in platelets, and has been extensively studied in the past, relatively little information is available on the expression, substrate specificity, and function of protein-tyrosine phosphatases.6 Only 3 enzymes, of a superfamily including more than 90 members, have been described in platelets: PTP-1B, SHP-1, and SHP-2. PTP-1B is the most abundant phosphatase in platelets, and is activated by calpain-dependent proteolysis or by interaction with the cytoskeleton during integrin IIbß3-dependent aggregation.7,8 Only 2 substrates for PTP-1B have been unambiguously identified in platelets: the adaptor protein LAT and the tyrosine kinase c-Src.9,10 While the late dephosphorylation of LAT is associated with the negative regulation of platelet activation induced by clustering of the low-affinity receptor for immunoglobulin G, FcRIIA,9 activation of c-Src by dephosphorylation of Tyr529 occurs upon fibrinogen binding to platelets, and implicates PTP-1B in the positive regulation of integrin IIbß3 outside-in signaling.10 SHP-1 and SHP-2 are SH2 domain–containing tyrosine phosphatases.11 In thrombin- or collagen-stimulated platelets, SHP-1 interacts with the cytoskeleton and associates with c-Src.12,13 SHP-1 is activated by tyrosine phosphorylation, and negatively regulated by PKC-directed serine phosphorylation.14,15 During platelet aggregation, both SHP-1 and SHP-2 can be activated by interaction with the tyrosine-phosphorylated intracellular domain of the membrane receptor PECAM-1.16 Although many substrates for SH2-containing phosphatases have been identified in nucleated cells, only Vav and -actinin have been demonstrated to be dephosphorylated by SHP-1 in platelets.15,17 In addition, a reduced, rather than increased, protein phosphorylation has been observed in collagen-stimulated platelets from mice expressing a catalytic inactive form of SHP-1, suggesting a positive role in platelet activation.18 The low-molecular-weight protein tyrosine phosphatase (LMW-PTP) is a cytosolic 18-kDa enzyme that has so far attracted relatively little attention.19 This protein is widely expressed in multiple isoforms derived by alternative splicing, and shows little sequence similarities to other known phosphatases, apart from a common CX5R motive in the active site and an identical catalytic mechanism.19 Although generally referred to as a cytosolic enzyme, LMW-PTP dynamically localizes in the cytoskeleton of activated cells.20 In transfected fibroblasts, LMW-PTP has been implicated in the regulation of growth factor–induced cell stimulation. Activated membrane receptors for PDGF, FGF, MCSF, insulin, and ephrins are, indeed, substrates for LMW-PTP.20–24 In addition, the enzyme can efficiently dephosphorylate p190RhoGAP and p120FAK, suggesting a role in the control of cell adhesion and spreading.25,26 Regulation of LMW-PTP is complex, and involves c-Src–directed tyrosine phosphorylation, interaction with the cytoskeleton, and redox modification.20,27–29 In this work, we have investigated the expression and function of LMW-PTP in circulating platelets and in DAMI megakaryocytic cells. We report that LMW-PTP is actually expressed in these cells and plays a crucial role in the regulation of cell activation downstream of immunoreceptor tyrosine–based activation motif (ITAM)–containing receptors.    Materials and methods Top Abstract Introduction Materials and methods Results Discussion Authorship References   Materials Sepharose CL-2B and protein G–Sepharose were from GE Healthcare (Cologno Monzese, Italy). FURA-2-AM was from Calbiochem (Milan, Italy). Thrombin, protein A–Sepharose, and anti–mouse IgG F(ab')2 fragments were from Sigma (Milan, Italy). Convulxin was provided by Dr K. J. Clemetson (Theodor Kocher Institute, University of Berne, Switzerland). Rabbit polyclonal anti–LMW-PTP antibody was prepared as previously described.30 Human recombinant LMW-PTP was expressed in E coli, and purified as previously described31; 1U defines the amount of enzyme able to hydrolyze 1 µmol p-nitrophenyl phosphate in 1 minute at 37°C and pH 5.5. Phosphotyrosine monoclonal antibody 4G10, anti-LAT, and anti–FcR -chain polyclonal antibodies were from Upstate Biotechnology (Lake Placid, NY). Polyclonal antibodies against FcRIIA and phospholipase C 2 (PLC2), and monoclonal antibody against Syk were from Santa Cruz Biotechnology (purchased through Tebu-Bio, Magenta, Italy). Monoclonal antibody IV.3 was from Medarex (Annandale, NJ). The rabbit polyclonal antibody against phospho-(Ser)-PKC substrates was from Cell Signaling Technology (purchased through Celbio, Pero, Italy). Appropriate peroxidase-conjugated anti-IgG antibodies were from Bio-Rad (Milan, Italy). Lipofectamine 2000 was from Invitrogen (Milan, Italy). Hygromycin was from Serva (purchased through Celbio). Platelet isolation and stimulation Samples were obtained from the Immunohematology and Transfusion Service, IRCCS Policlinico San Matteo, University of Pavia (Pavia, Italy), where blood was withdrawn from healthy volunteers, using 10% citric acid—citrate–dextrose as anticoagulant. Samples were centrifuged at 120g for 10 minutes at room temperature to obtain the platelet-rich plasma. Upon addition of 0.02 U/mL apyrase and 1 µM PGE1, the platelet-rich plasma was centrifuged at 720g for 15 minutes. The platelet pellet was washed with PIPES buffer (20 mM PIPES, 136 mM NaCl, pH 6.5), centrifuged at 600g for 15 minutes, and finally resuspended in HEPES buffer (10 mM HEPES, 137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, pH 7.4). The cell count was adjusted to 1 x 109 platelets/mL with HEPES buffer. Platelet stimulation was performed at 37°C under gentle stirring with thrombin (1 U/mL, 1 minute) or convulxin (100 ng/mL, 1 minute), or by clustering of FcRIIA, obtained by addition of 2 µg/mL IV.3 monoclonal antibody for 2 minutes followed by 30 µg/mL sheep antimouse F(ab')2 fragments for 1 minute. Cell lines DAMI human megakaryocytic cells were routinely cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, L-glutamine, and antibiotics (penicillin/streptomycin). The PTP13 DAMI cell clone overexpressing LMW-PTP has been previously described.32 A DAMI cell clone with a reduced expression of LMW-PTP was generated by siRNA interference. The pRNAT-U6.1/Hygro vector containing the siRNA 5'-CAGCGGTGCTGTTTCTGACTG-3' (sense sequence) under the control of the U6 promoter was obtained from GenScript (Piscataway, NJ). As a negative control, a plasmid containing the scrambled sequence 5'-GTCGGCTGGTATCTTACGTGC-3' was used. Cells (0.5 x 105) were plated in 0.5 mL RPMI without serum and transfected with 1 µg DNA plus 4 µL Lipofectamine 2000. After 24 hours, cells were given complete medium and, after 48 hours, selection was started by adding 100 µg/mL hygromycin. DAMI S2C cell clone displaying a 50% reduction in LMW-PTP content (as evaluated from immunoblotting with anti–LMW-PTP antibody) was so obtained. Stable suppression was maintained by periodically growing the cells in selective medium. v-src–transformed NIH3T3 murine fibroblasts expressing LMW-PTP were obtained and cultured as previously described.27 Immunoprecipitation and immunoblotting Platelet samples (0.3 mL) were stimulated at 37°C with convulxin or by cross-linking of FcRIIA. DAMI cells were serum starved for 24 hours in RPMI containing 1% BSA, washed with PBS, and resuspended at the final concentration of 2 x 107 cells/mL. Cells in 0.2-mL samples were stimulated by cross-linking of FcRIIA for increasing time periods. Platelet or cell stimulation was stopped by addition of an equal volume of ice-cold 2 x lysis buffer (100 mM Tris, pH 7.4, 300 mM NaCl, 2 mM EGTA, 2% nonidet P-40, 0.5% sodium deoxycholate, 2 mM PMSF, 2 mM NaF, 5 µg/mL leupeptin, 5 µg/mL aprotinin, 2 mM Na3VO4), and samples were placed on ice for 10 minutes. Immunoprecipitation of Syk, PLC2, LAT, FcRIIA, or FcR -chain was then performed essentially as previously described.33 Immunoprecipitated proteins were then separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% linear or 10% to 20% gradient acrylamide gels, transferred to nitrocellulose, and analyzed by immunoblotting with antiphosphotyrosine antibody as previously described.33 Upon stripping, membranes were reprobed with the same antibody used for the immunoprecipitation. For analysis of LMW-PTP expression in platelets, whole lysates were obtained by addition of 2% SDS to platelet samples. Upon determination of protein concentration by the bicinchoninic acid assay, aliquots of the lysates were analyzed by immunoblotting with anti–LMW-PTP antibody. This was performed through the same procedure for immunoblotting as previously described,33 using the anti–LMW-PTP antibody at a 1:1000 final dilution and appropriate peroxidase-conjugated anti–rabbit IgG antibody. All the reported figures are representative of results obtained at least in 3 different experiments. Analysis of LMW-PTP–mediated dephosphorylation of platelet substrates Platelet samples (0.1 mL) were stimulated with thrombin or convulxin, or by clustering of FcRIIA, as indicated above, and reactions were stopped by addition of an equal volume of 2 x lysis buffer. Identical aliquots of the lysates were incubated in the absence or in the presence of 5 U/mL purified recombinant LMW-PTP31 at 30°C for 5 minutes. At the end of the incubation, an equal volume of SDS-sample buffer was added, and samples were heated at 96°C for 3 minutes. The level of protein tyrosine phosphorylation in identical aliquots from each sample was evaluated by immunoblotting with an antiphosphotyrosine antibody. Syk, PLC2, LAT, FcRIIA, and FcR -chain were immunoprecipitated from platelets stimulated by cross-linking of FcRIIA or with convulxin, as described above. Immunoprecipitated Syk, PLC2, and FcRIIA, immobilized on protein A-Sepharose, were resuspended in 50 µL 0.1-M sodium acetate, pH 5.5, 1 mM EDTA, and 1 mM DTT. LAT and FcR -chain were resuspended in 50 µL 62-mM HEPES, pH 7.0, 0.2 M NaCl, 1 mM EDTA, and 5 mM DTT. This different buffer was adopted, because in preliminary experiments it was found more suitable in order to minimize a nonspecific loss of the phosphate group from these immunoprecipitated proteins during the following incubation at 30°C. Proteins were then incubated in the absence or presence of 5 U/mL purified recombinant LMW-PTP at 30°C for 30 minutes. The reaction was terminated by centrifugation at 17 900g for 30 seconds, and the supernatants were removed. The pellets were dissociated with SDS-sample buffer and heated at 96°C for 3 minutes. The tyrosine phosphorylation of the immunoprecipitated proteins was then determined by immunoblotting with an antiphosphotyrosine antibody. Alternatively, immunoprecipitated proteins were immediately separated by SDS-PAGE and transferred to nitrocellulose. Membranes were subsequently incubated with or without 1 U/mL LMW-PTP (in 0.2 mL 0.1-M sodium acetate, pH 5.5, 1 mM EDTA, 1 mM DTT for Syk, PLC2, and FcRIIA or 62 mM HEPES, pH 7.0, 0.2 M NaCl, 1 mM EDTA, 5 mM DTT for LAT and FcR-chain), for 1 hour at room temperature. After extensive washing, nitrocellulose membranes were incubated with a specific antibody in order to determine the level of tyrosine phosphorylation of immunoprecipitated proteins. Quantitative analysis of LMW-PTP–mediated dephosphorylation of the immunoprecipitated substrates was performed by densitometric analysis of 3 to 5 different experiments for each protein. Subcellular fractionation Membrane and cytosolic fractions were rapidly separated essentially as described.34 Briefly, platelets (0.2 mL) were lysed with 0.05% digitonin in PBS, pH 7.4, and centrifuged at 17 900g for 1 minute. The supernatants (cytosolic fractions) were removed and collected. The pellets (membrane-rich fractions, also containing membrane skeleton and membrane-associated cytoskeleton) were resuspended in an equal volume of PBS containing 0.05% digitonin. Cytosolic and membrane fractions were finally dissociated with 2% SDS, and heated at 96°C for 3 minutes. Cytoskeleton was extracted from resting and stimulated platelets (0.4 mL) upon lysis with 1% Triton X-100, and was isolated by high-speed centrifugation, as previously described.35 Membrane, cytosolic, and cytoskeletal proteins from aliquots of each sample corresponding to the same number of platelets were separated on a 10% to 20% SDS-PAGE and analyzed by immunoblotting with anti–LMW-PTP antibody. Measurement of cytosolic Ca2+ concentration and PKC-dependent protein phosphorylation in DAMI cells Serum-starved cells (5 x 106 cells/mL) were loaded with 3 µM FURA-2-AM in RPMI containing 1% BSA for 1 hour at 37°C. Cells were then washed and resuspended in HEPES buffer containing 0.5% BSA and 5.5 mM glucose at the final concentration of 2 x 106 cells/mL. Measurement of cytosolic Ca2+ was performed on 0.4-mL samples prewarmed at 37°C under gentle stirring in a PerkinElmer Life Sciences LS3 spectrofluorometer (Shelton, CT), essentially as previously described.36    Results Top Abstract Introduction Materials and methods Results Discussion Authorship References   Expression of LMW-PTP in human platelets Platelet lysates from 4 different donors were analyzed by immunoblotting with a polyclonal antibody against LMW-PTP. Figure 1A shows that a major, single, and strong band with a molecular mass of about 20 kDa was detected in all the samples with a comparable intensity. This band had the same electrophoretic mobility as the purified phosphatase (Figure 1B). In order to quantify the expression of LMW-PTP, increasing amounts of the purified, recombinant enzyme and total platelet lysates were loaded on the same gel, and analyzed by immunoblotting (Figure 1B). By densitometric analysis, we calculated that 107 platelets contained 8.2 ± 1.7 ng (n = 4) LMW-PTP, which represents about 0.05% of the total cell proteins. View larger version (32K): [in this window] [in a new window]   Figure 1. Expression of LMW-PTP in human platelets. (A) Aliquots (40 µg) of whole platelet lysates from 4 different donors (A-D) were separated by SDS-PAGE on a 10% to 20% acrylamide gradient gel, transferred to nitrocellulose, and probed with a polyclonal antibody against LMW-PTP. As a control for the specificity of the anti–LMW-PTP antibody, platelet proteins from the donor A were analyzed by identical immunoblotting procedure, but in the absence of primary antibody (lane A* on the left). The band corresponding to LMW-PTP is indicated on the right, and the migration of molecular mass markers is reported on the left. (B) In order to quantify the amount of LMW-PTP expressed in platelets, immunoblotting analysis with the anti–LMW-PTP antibody was performed upon loading on the same gel of increasing amounts of total platelet proteins, corresponding to the indicated number of cells, and of known amounts of purified recombinant LMW-PTP.   We next investigated whether endogenous substrates for LMW-PTP are present in human platelets. In order to analyze different subsets of tyrosine-phosphorylated proteins, platelets were treated with 3 different agonists: thrombin, convulxin, and antibodies able to cross-link the FcRIIA. Aliquots of cell lysates were incubated in the absence or presence of purified recombinant LMW-PTP for 5 minutes. Immunoblotting analysis with antiphosphotyrosine antibody revealed a single band of about 60 kDa in nonstimulated platelets. This protein presumably corresponded to pp60src, which is known to be abundant and constitutively phosphorylated in platelets, and was not affected by incubation with LMW-PTP (Figure 2). In stimulated platelets, multiple substrates were tyrosine phosphorylated, and many of them underwent evident dephosphorylation upon incubation with LMW-PTP. As documented by a number of previous publications,4,33,37 we have been interested for a long time in the role of FcRIIA in platelet activation, a process that is critically dependent on tyrosine phosphorylation of many intracellular effectors, including the receptor itself. Therefore, although LMW-PTP appeared to selectively recognize multiple substrates in cells stimulated with all the agonists analyzed, we decided to focus our further investigations on platelets activated by clustering of FcRIIA, where many of the substrates promptly dephosphorylated by LMW-PTP showed a molecular mass ranging between 30 and 50 kDa. View larger version (26K): [in this window] [in a new window]   Figure 2. Dephosphorylation of platelet substrates by LMW-PTP. Protein-tyrosine phosphorylation was induced by stimulation of washed platelets with 1 U/mL thrombin or 100 ng/mL convulxin or by FcRIIA clustering, obtained by addition of 2 µg/mL IV.3 monoclonal antibody and 30 µg/mL sheep antimouse F(ab')2 fragments, as indicated on the top. Identical aliquots of the platelet lysates from stimulated platelets, but also from nonstimulated platelets (Bas), were incubated in the absence (–) or in the presence (+) of 5 U/mL purified LMW-PTP at 30°C for 5 minutes, as indicated on the bottom. Upon protein separation on a 10% to 20% acrylamide gradient gel, the level of protein-tyrosine phosphorylation was analyzed by immunoblotting with antiphosphotyrosine antibody. In the lane corresponding to the samples stimulated with convulxin, the phosphorylation of the protein in the low range of molecular masses, where FcR -chain migrates, is reported as a separated panel, because a prolonged exposure has been necessary to detect the reported band. Since platelet stimulation by FcRIIA clustering involves addition of IV.3 monoclonal antibody, but also of a higher amounts of F(ab')2 fragments, cross-reactivity with the peroxidase-conjugated secondary antibody is expected when whole platelet lysates are tested with antiphosphotyrosine monoclonal antibody (A). Therefore, in panel B, a corresponding immunoblot where the primary antibody was omitted is reported as a control, and shows that the major band at about 20 kDa represents probably the single chains of the antibody and F(ab')2 fragments added to the platelet samples. All the reported results are representative of at least 3 different experiments.   LMW-PTP dephosphorylates activated FcRIIA and LAT We next investigated the ability of LMW-PTP to dephosphorylate selected elements in the signal transduction pathway initiated by FcRIIA: the receptor itself, the tyrosine kinase Syk, the adaptor protein LAT, and the enzyme PLC2.38,39 These proteins were immunoprecipitated from stimulated platelets, and immobilized on nitrocellulose by Western blotting. Membranes were incubated with or without recombinant LMW-PTP for 30 minutes, and the level of tyrosine phosphorylation of the proteins was evaluated by immunoblotting. Figure 3A shows that immobilized FcRIIA and LAT underwent evident dephosphorylation when incubated with LMW-PTP, while Syk and PLC2 did not. In a different approach, the immunoprecipitated proteins were directly incubated with LMW-PTP in solution, and then subjected to SDS-PAGE and immunoblotting with the antiphosphotyrosine antibody. In this way, we confirmed that FcRIIA and LAT, but not Syk or PLC2, were efficiently dephosphorylated by LMW-PTP (Figure 3B). It is well known that tyrosine phosphorylation of FcRIIA occurs within the ITAM.36,38 In addition to FcRIIA, platelets express another ITAM-bearing receptor, the FcR -chain, which is associated with GPVI and is phosphorylated upon platelet stimulation with collagen or convulxin.3,40,41 Although some dephosphorylation of FcR -chain was observed upon incubation with LMW-PTP both in solution and upon immobilization on nitrocellulose (Figure 3A,B), this effect was marginal compared with that seen on FcRIIA or LAT. Quantification of LMW-PTP–mediated dephosphorylation was evaluated by densitometric analysis, and is reported in Figure 3C. It is confirmed that LAT, but not Syk or PLC2, was dephosphorylated by LMW-PTP, with a greater efficiency when the protein and the enzyme were incubated in solution. In addition, it is evident that LMW-PTP had no significant effects on FcR -chain. These results, however, indicate that LMW-PTP can act as negative regulator of FcRIIA. View larger version (23K): [in this window] [in a new window]   Figure 3. Identification of platelet substrates for LMW-PTP. FcRIIA, Syk, LAT, and PLC2 were immunoprecipitated from platelets stimulated by clustering of FcRIIA (2 µg/mL IV.3 monoclonal antibody and 30 µg/mL antimouse F(ab')2 fragments), while FcR -chain was immunoprecipitated upon platelet stimulation with 100 ng/mL convulxin. Immunoprecipitated proteins were separated by SDS-PAGE and transferred to nitrocellulose. Membranes were then incubated in the absence or presence of purified LMW-PTP for 30 minutes (A). Alternatively, the immunoprecipitated proteins immobilized on protein A–Sepharose were incubated in the absence or presence of purified LMW-PTP for 30 minutes and subsequently separated by SDS-PAGE (B). The level of tyrosine phosphorylation of the immunoprecipitated proteins was then evaluated by immunoblotting with antiphosphotyrosine antibody, and, upon stripping, each membrane was reprobed with the same antibody used for the immunoprecipitation, as reported on the right of each panel. In panel C, a quantification of the residual phosphorylation of the analyzed substrates after incubation with LMW-PTP on nitrocellulose () or in solution () is reported. The level of phosphorylation of each single protein in the absence of LMW-PTP is taken as 100%. The data are reported as mean plus or minus SD of 3 to 5 different experiments for each protein.   Regulation of LMW-PTP in FcRIIA-stimulated platelets Since LMW-PTP dephosphorylates critical players in the signal transduction pathway activated by FcRIIA, we investigated whether this phosphatase could be directly targeted by engagement of this receptor. It has been previously shown that enzymatic activity of LMW-PTP is stimulated by Src-mediated tyrosine phosphorylation.27,28 By immunoprecipitation and immunoblotting experiments, however, we found that, in platelets, LMW-PTP was not tyrosine phosphorylated upon clustering of FcRIIA (Figure 4Ai) or upon stimulation with thrombin or convulxin (data not shown). Concomitant evaluation of platelet aggregation confirmed the effective activation of platelets stimulated by clustering of FcRIIA (Figure 4Ai). Although we have been unable to observe tyrosine phosphorylation of LMW-PTP even in platelets treated with pervanadate (data not shown), previous works have documented that the antiphosphotyrosine antibody used in this study is actually suitable to detect the phosphorylated form of LMW-PTP.42 Moreover, we also documented phosphorylation of LMW-PTP immunoprecipitated from v-src–transformed NIH3T3 cells by immunoblotting with antiphosphotyrosine antibody (Figure 4Aii). These results, therefore, demonstrate that neither platelet activation nor aggregation can trigger LMW-PTP tyrosine phosphorylation. In fibroblasts, LMW-PTP has been reported to be regulated through interaction with the cytoskeleton,25 and, in platelets, the cytoskeleton is known to coordinate several signaling molecules.43 Upon platelet stimulation by clustering of FcRIIA, LMW-PTP underwent a transient and time-dependent translocation to the cytoskeleton, which was maximal within 60 seconds, as aggregation reached about 90%, and decreased afterward (Figure 4B). A similar time-dependent translocation of LMW-PTP to the cytoskeleton was also seen in platelets stimulated with thrombin or convulxin (data not shown). View larger version (30K): [in this window] [in a new window]   Figure 4. Regulation of LMW-PTP in FcRIIA-stimulated platelets. (Ai). Platelets were stimulated in a lumiaggregometer by clustering of FcRIIA (2 µg/mL IV.3 monoclonal antibody and 30 µg/mL antimouse F(ab')2 fragments) for increasing times. Upon immunoprecipitation with the specific antibody against LMW-PTP, or with unrelated IgG used as negative control, the level of tyrosine phosphorylation was investigated by immunoblotting, as indicated on the right. The percentage of platelet aggregation measured in each stimulated sample is reported on the bottom. (ii) Lysates from v-src–transformed NIH3T3 cells were immunoprecipitated with anti–LMW-PTP antibody (lane 1) or with control, unrelated IgG (lane 2). Immunoprecipitated proteins were analyzed by immunoblotting with antiphosphotyrosine antibody (P-Tyr, top panel) and with anti–LMW-PTP antibody (bottom panel). (B) Platelet stimulation by clustering of FcRIIA was performed in a lumiaggregometer, and was stopped at the indicated times. Upon cell lysis, the intracellular cytoskeleton was isolated as Triton-X-100–insoluble material. The association of LMW-PTP with the cytoskeleton was analyzed by immunoblotting with anti–LMW-PTP polyclonal antibodies. The figure also shows the percentage of platelet aggregation measured in each sample. (C) Cytosol (cyt) and membrane-rich fractions (memb) were separated from platelets stimulated by clustering of FcRIIA for the indicated times. The subcellular redistribution of LMW-PTP was investigated by immunoblotting with the specific polyclonal antibodies. All these experiments have been repeated at least 3 times.   We next analyzed the distribution of LMW-PTP between the cytosol and the membrane-rich fraction. In resting platelets, LMW-PTP was almost exclusively present in the cytosol, but an evident, time-dependent translocation to the membrane-rich fraction was seen upon platelet stimulation by clustering of FcRIIA (Figure 4C). Altogether, these results indicate that the subcellular distribution of LMW-PTP is dynamically regulated upon platelet activation. In particular, the different kinetics reported in Figure 4B,C indicate that upon stimulation of FcRIIA, interaction of LMW-PTP with the intracellular actin-based cytoskeleton precedes its association with the membrane fraction. LMW-PTP–dependent dephosphorylation of FcRIIA in stimulated cells In order to get further insights into the physiological role of LMW-PTP in the regulation of FcRIIA-mediated cell activation, we analyzed 2 different clones of the megakaryocytic cell line DAMI: the PTP13 clone, overexpressing the phosphatase, and the S2C clone, in which expression of LMW-PTP was reduced by siRNA. By immunoblotting analysis, we confirmed that in comparison with wild-type cells, the expression of LMW-PTP was reduced in the S2C and increased in the PTP13 clones, and we verified that all these cells expressed comparable levels of FcRIIA (Figure 5A). View larger version (35K): [in this window] [in a new window]   Figure 5. Regulation of FcRIIA tyrosine phosphorylation by LMW-PTP in DAMI megakaryocytic cells. (A) The expression of LMW-PTP and FcRIIA in wild-type DAMI cells, as well as in the clones S2C and PTP13, was analyzed on 20 µg of whole cell lysates by immunoblotting with specific antibodies as indicated on the right. (B) Wild-type, S2C, and PTP13 DAMI cells were stimulated by clustering of FcRIIA (2 µg/mL IV.3 monoclonal antibody and 30 µg/mL antimouse F(ab')2 fragments) for increasing times. Upon cell lysis, FcRIIA was immunoprecipitated and the level of tyrosine phosphorylation of the receptor was analyzed by immunoblotting with antiphosphotyrosine antibody, as indicated on the right. Upon stripping, the efficiency of the immunoprecipitation was verified by reprobing the membranes with anti- FcRIIA antibody. (C) Comparison of the kinetics of FcRIIA tyrosine phosphorylation in wild-type (), S2C (), and PTP12 () DAMI cells stimulated by clustering of FcRIIA. Data are the means plus or minus SD obtained from the densitometric analysis of 3 to 5 different immunoblots similar to those reported in panel B, and have been normalized based on an experiment in which samples at a single time point for all the 3 clones have been analyzed on the same immunoblot. The asterisk indicates that the differences between the S2C or the PTP13 clones and wild-type cells are statistically significant (P < .05).   Figure 5B,C show the kinetics of antibody-induced FcRIIA tyrosine phosphorylation in DAMI cells. Figure 5B reports some representative immunoblots, whereas Figure 5C summarizes data from 3 to 5 different experiments. In wild-type cells, clustering of FcRIIA caused a rapid and transient tyrosine phosphorylation of the receptor, which persisted up to 45 seconds, and was followed by a complete dephosphorylation within 2 minutes. In our experiments with DAMI cells, the antiphosphotyrosine antibody detected an additional band of slightly higher molecular mass in immunoprecipitated FcRIIA. The identity of this band is currently unknown, but it may represent either a differently glycosylated form of FcRIIA itself or a FcRIIA-associated protein. In the S2C clone with reduced expression of LMW-PTP, the initial rapid antibody-induced tyrosine phosphorylation of the receptor was not altered, but the subsequent dephosphorylation was impaired and incomplete even after 5 minutes. By contrast, in the PTP13 clone, overexpression of LMW-PTP was associated with a reduced initial phosphorylation of FcRIIA and to a more rapid dephosphorylation, which was already complete within 45 seconds (Figure 5B). Down-regulation of FcRIIA-dependent cell activation by LMW-PTP We next investigated the effect of LMW-PTP suppression or overexpression on intracellular signaling events elicited by FcRIIA engagement. It is well known that tyrosine-phosphorylated FcRIIA binds the kinase Syk, which is activated by autophosphorylation, and contributes to the phosphorylation and activation of PLC2.38,44,45 Figure 6 shows that dephosphorylation of Syk on tyrosine residues was accelerated in the DAMI cells overexpressing LMW-PTP (clone PTP13), and delayed when the expression of the phosphatase was reduced (clone S2C). Interestingly, the kinetics of Syk phosphorylation in the 3 different clones of DAMI megakaryocytic cells was superimposable to that of FcRIIA (Figure 5B). Since Syk is not a direct substrate for LMW-PTP (Figure 3A,B), these results reflect the altered upstream regulation of the FcRIIA, rather than a direct action on Syk itself. View larger version (32K): [in this window] [in a new window]   Figure 6. Analysis of Syk tyrosine phosphorylation in DAMI cells. (A) The 3 different clones of DAMI megakaryocytic cells (wild type, S2C, and PTP13) were stimulated by clustering of FcRIIA (2 µg/mL IV.3 monoclonal antibody and 30 µg/mL antimouse F(ab')2 fragments) for the indicated times. The tyrosine kinase Syk was then immunoprecipitated and subjected to immunoblotting analysis with antiphosphotyrosine antibody and, upon stripping of the nitrocellulose, with anti-Syk antibody, as indicated on the right. (B) Comparison of the kinetics of Syk phosphorylation in wild-type (), S2C (), and PTP12 () DAMI cells stimulated by clustering of FcRIIA, as evaluated by densitometric analysis of the results of 3 different experiments. Results are reported as means plus or minus SD and have been normalized based on an experiment in which samples at a single time point for all the 3 clones have been analyzed on the same immunoblot.   We next investigated the activation of PLC triggered by clustering of FcRIIA in DAMI cells, by measuring the release of Ca2+ from intracellular stores. The initial rapid and transient increase of cytosolic Ca2+ in FcRIIA-stimulated cells was not altered when the expression of LMW-PTP was reduced, but was clearly inhibited in the PTP13 clone, overexpressing LMW-PTP (Figure 7A). As expected, all 3 clones underwent comparable increase of the intracellular Ca2+ concentration upon stimulation with thrombin (Figure 7A). Although signaling through activated FcRIIA has been previously found to potentiate Ca2+ signaling induced by low doses of thrombin,33 at the high concentration used in the present experiments (1 U/mL), thrombin-induced intracellular Ca2+ mobilization was recognized to occur mainly through G-protein–mediated stimulation of PLCß isoforms rather than through stimulation of PLC2 by ITAM-dependent signaling.33 These results indicate that overexpression of LMW-PTP results in an impaired PLC activity downstream of FcRIIA engagement. View larger version (24K): [in this window] [in a new window]   Figure 7. Analysis of FcRIIA-induced PLC activation in DAMI cell clones differently expressing LMW-PTP. Intracellular Ca2+ increase was measured using DAMI cells (wild type, S2C, or PTP13 clones, as indicated) loaded with FURA-2-AM, and stimulated by clustering of FcRIIA with 2 µg/mL IV.3 monoclonal antibody and 30 µg/mL antimouse F(ab')2 fragments (traces on the left) or with 1 U/mL thrombin (traces on the right). Representative results of at least 3 similar experiments are reported.      Discussion Top Abstract Introduction Materials and methods Results Discussion Authorship References   In this work, we have identified LMW-PTP as a cytosolic protein tyrosine phosphatase expressed in human platelets, and we have found that this enzyme can efficiently dephosphorylate the ITAM-bearing FcRIIA, both in vitro and in vivo. This action has relevant consequences on the final outcome of cell response to FcRIIA engagement, as LMW-PTP–mediated dephosphorylation of the receptor was found to affect the correct organization of the intracellular signaling pathway for the propagation of the activating signal, eventually resulting in a defective PLC activation and altered second messenger generation. In addition, we have found that LMW-PTP may also promote, at least in vitro, the dephosphorylation of FcR -chain, the ITAM-containing subunit of the collagen receptor GPVI. Therefore, LMW-PTP may represent a new versatile and important regulator of platelet activation through immunoreceptors. We calculated that, in platelets, LMW-PTP accounts for about 0.05% of the total platelet proteins, and, thus, it appears less abundant than other phosphatases, such as PTP-1B, which was reported to represent 0.2% of the platelet proteins.7 However, LMW-PTP represents, to our knowledge, the first described enzyme able to dephosphorylate FcRIIA, and to negatively regulate cell activation triggered by this immunoreceptor. FcRIIA is a 40-kDa single-chain transmembrane receptor, with 2 IgG-like motifs in the extracellular domain and a ITAM in the short cytoplasmic sequence.46 When cross-linked by immunocomplexes, as it occurs in some autoimmune diseases or during heparin-induced thrombocytopenia, it initiates an intracellular signaling pathway similar to the one elicited by other immunoreceptors in B and T lymphocytes.38,46 Tyrosine-phosphorylated ITAM of FcRIIA recruits and activates the tyrosine kinase Syk, which propagates the signal through the adaptor protein LAT and the enzyme PLC2. Eventually, PLC-driven intracellular Ca2+ mobilization and PKC activation trigger platelet secretion and aggregation. Using a megakaryocytic cell line model, we have demonstrated that dephosphorylation of FcRIIA by LMW-PTP efficiently dampens the downstream signaling cascade and attenuates activation of both Syk and PLC2. Activation of Syk has been evaluated by measuring its tyrosine phosphorylation, whose intensity and duration have been found to be influenced by the altered LMW-PTP expression. It should be noted that LMW-PTP is unable to directly target Syk, as demonstrated by in vitro dephosphorylation assays. Therefore, the alteration of the levels of Syk phosphorylation is most likely a consequence of the effects of LMW-PTP on FcRIIA phosphorylation. Altogether, our results indicate that by targeting the phosphorylated ITAM, LMW-PTP may regulate the overall cellular response to FcRIIA engagement. While overexpression of LMW-PTP was clearly associated with inhibition of FcRIIA-mediated cell activation, the reduced expression of the phosphatase caused a prolonged activation of Syk, but did not result in any evident potentiation of PLC activation. Identical results were obtained from the analysis of a different DAMI clone, S27, with a comparable reduction of LMW-PTP expression, obtained by siRNA, ruling out the possibility that this lack of effect on cell activation was related to the particular clone analyzed (data not shown). It is, however, reasonable to suppose that additional and more selective regulatory mechanisms predominate over the persistence of ITAM phosphorylation in the temporal regulation of IP3- and DAG-mediated effects. Nevertheless, the intensity of FcRIIA activation represents the original signal triggering the rapid PLC-dependent response, and, in this context, our findings are consistent with the observation that the initial rapid phosphorylation of FcRIIA was unaltered in the cells expressing a reduced level of LMW-PTP. The ability of LMW-PTP to dephosphorylate FcRIIA may appear particularly relevant in light of a number of recent pieces of evidence implicating this receptor in numerous and diverse processes of platelet activation. In fact, the ITAM-orchestrated signaling pathway involving Syk, LAT, and PLC2 represents a signaling cassette widely exploited by many agonists in order to elicit full platelet activation. In particular, many studies have documented the direct involvement of ITAM-bearing receptors in VWF-GPIb-IX-V–dependent platelet activation,47–49 in integrin outside-in signaling,50 as well as in platelet stimulation downstream of G-protein–coupled receptors.33,51 In this regard, it is interesting to note that LMW-PTP was found to dephosphorylate substrates in thrombin-stimulated platelets with molecular masses comparable with those detected upon clustering of FcRIIA. This observation may be explained in the light of the previous finding that ITAM-mediated signaling initiated by transactivation of FcRIIA in thrombin-stimulated platelets significantly contributes to the agonist-induced protein tyrosine phosphorylation, and potentiates platelet response to low doses of the agonist.33 It is therefore possible that LMW-PTP exerts a more widespread and general negative control on platelet function. This intriguing possibility, however, deserves further investigation. Other tyrosine phosphatases may be involved in regulation of platelet activation by immunoreceptors as well, but their precise contribution has not been clearly demonstrated. In particular the SH2 domain–containing phosphatases SHP-1 and SHP-2 are known to be activated in stimulated platelets by binding to the tyrosine-phosphorylated ITIM-containing receptor PECAM-1.16,52,53 Although in B cells SHP-1 negatively regulates BCR-dependent signaling,54 there is no evidence that it can dephosphorylate ITAM-bearing receptors in platelets. Moreover, loss of catalytic activity of SHP-1 in mev/mev mice was found to cause an unexpected platelet hyporeactivity to collagen.18 PTP-1B has been proposed to regulate FcRIIA-mediated platelet aggregation by promoting dephosphorylation of LAT.9 Interestingly, we have found in this work that LAT is also a good substrate for LMW-PTP. In this context, the reported ability of LMW-PTP remains unique and peculiar, as it may regulate platelet activation at 2 different levels in the signaling pathway initiated by phosphorylated ITAM. Other tyrosine phosphatases expressed in platelets are typically regulated by means of tyrosine phosphorylation, calpain-mediated proteolysis, or cytoskeleton interaction. LMW-PTP possesses 2 adjacent tyrosine residues, Tyr132 and Tyr133, and a strong increase of the enzymatic activity has been found to be associated with phosphorylation of Tyr132.27,28 However, we failed to detect any tyrosine phosphorylation of LMW-PTP upon FcRIIA clustering. We found, by contrast, that LMW-PTP underwent an evident subcellular redistribution in FcRIIA-stimulated platelets, as it was found to translocate from the cytosol to the membrane fraction and to interact with the intracellular cytoskeleton. It seems therefore most likely that upon FcRIIA engagement, LMW-PTP undergoes regulation through cellular redistribution rather than by covalent modification. In this context, interaction with the cytoskeleton may be critical, as it appears to precede membrane translocation. LMW-PTP interaction with the cytoskeleton has also been reported to occur in nucleated cells, and it has been shown to be important in determining substrate accessibility.19,20 In stimulated platelets, the intracellular cytoskeleton interacts with several membrane glycoproteins and with elements of the membranoskeleton.43 It should be noted that in our study the rapid separation of the membrane-rich fraction from the cytosol was obtained upon platelet treatment with low concentrations of the weak detergent digitonin, according to a previously published procedure.35 Since this treatment is most likely to preserve membrane interaction with the cytoskeleton in stimulated platelets, our membrane-rich fractions also contain the cytoskeletal elements that have interacted with membrane components. It is therefore possible that upon FcRIIA cross-linking, the reorganized actin-based network recruits LMW-PTP from the cytosol in order to subsequently convey it to its physiological substrate at the membrane level. The possible regulation of LMW-PTP by interaction with the cytoskeleton is consistent with the evidence, that, as a down-regulator of platelet activation, it is recruited in a delayed phase of platelet activation. In this respect, LMW-PTP differs from SHP-1 or SHP-2, which are activated during the first seconds of platelet stimulation, but behaves similarly to PTP-1B whose activation by calpain-mediated proteolysis is temporally associated with platelet aggregation.7–9 In conclusion, we have identified a new tyrosine phosphatase expressed in human platelets, able to dephosphorylate the ITAM-bearing receptor FcRIIA, and we have provided new insights into the mechanism regulating immunoreceptor-triggered platelet activation. Because of the versatility of FcRIIA as signal transducer in many processes of platelet activation, LMW-PTP may represent an excellent target for new antithrombotic agents.    Authorship Top Abstract Introduction Materials and methods Results Discussion Authorship References   Contribution: F.M. designed and performed experiments, analyzed data, and wrote the paper; S.R. provided vital reagents, performed experiments, and edited the paper; A.B. contributed vital new reagents; C.B. analyzed data and edited the paper; M.T. designed research, analyzed data, wrote the paper, and provided overall direction. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Mauro Torti, Department of Biochemistry, University of Pavia, via Bassi 21, 27100 Pavia, Italy; e-mail: mtorti{at}unipv.it.    Acknowledgments   This work was supported by grants from the University of Pavia, and from the Consorzio Interuniversitario Biotecnologie (CIB). We thank Dr Ilaria Canobbio and Dr Paolo Lova (Department of Biochemistry, University of Pavia) for technical assistance and critical advice.    Footnotes   Submitted March 26, 2007; accepted May 29, 2007. Prepublished online as Blood First Edition Paper, May 30, 2007 DOI: 10.1182/blood-2007-03-081414 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results Discussion Authorship References   Feinstein MB, Pumiglia K, Lau LF. Tyrosine phosphorylation in platelets: its regulation and possible roles in platelet functions. Adv Exp Med Biol 1993; 344:129–148.[Medline] [Order article via Infotrieve] Lévy-Toledano S. Platelet signal transduction pathways: could we organize them into a ‘hierarchy’? Haemostasis 1999; 29:4–15.[CrossRef][Medline] [Order article via Infotrieve] Watson SP and Gibbins J. Collagen receptor signaling in platelets: extending the role of the ITAM. Immunol Today 1998; 19:260–264.[CrossRef][Medline] [Order article via Infotrieve] Canobbio I, Balduini C, Torti M. Signaling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 2004; 16:1329–1344.[CrossRef][Medline] [Order article via Infotrieve] Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin IIbß3 signaling in platelets. J Thromb Haemost 2005; 3:1752–1762.[CrossRef][Medline] [Order article via Infotrieve] Jackson SP, Schoenwaelder SM, Yuan Y, Salem HH, Cooray P. Non-receptor protein tyrosine kinases and phosphatases in human platelets. Thromb Haemost 1996; 76:640–650.[Medline] [Order article via Infotrieve] Frangioni JV, Oda A, Smith M, Salzman EW, Neel BG. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J 1993; 12:4843–4856.[Medline] [Order article via Infotrieve] Ezumi Y, Takayama H, Okuma M. Differential regulation of protein-tyrosine phosphatases by integrin IIbß3 through cytoskeletal reorganization and tyrosine phosphorylation in human platelets. J Biol Chem 1995; 270:11927–11934.[Abstract/Free Full Text] Ragab A, Bodin S, Viala C, Chap H, Payrastre B, Ragab-Thomas J. The tyrosine phosphatase1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcRIIA cross-linking. J Biol Chem 2003; 278:40923–40932.[Abstract/Free Full Text] Arias-Salgado EG, Haj F, Dubois C, et al. PTP-1B is an essential positive regulator of platelet integrin signaling. J Cell Biol 2005; 170:837–845.[Abstract/Free Full Text] Poole AW and Jones ML. A SHIPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signaling 2005; 17:1323–1332.[CrossRef][Medline] [Order article via Infotrieve] Li RY, Gaits F, Ragab A, Ragab-Thomas JM, Chap H. Translocation of an SH2-containing protein tyrosine phosphatase (SH-PTP1) to the cytoskeleton of thrombin-activated platelets. FEBS Lett 1994; 343:89–93.[CrossRef][Medline] [Order article via Infotrieve] Falet H, Ramos-Morales F, Bachelot C, Fischer S, Rendu F. Association of the protein tyrosine phosphatase PTP1C with the protein tyrosine kinase c-Src in human platelets. FEBS Lett 1996; 383:165–169.[CrossRef][Medline] [Order article via Infotrieve] Li YR, Gaits F, Ragab A, Ragab-Thomas JM, Chap H. Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussin toxin-sensitive heterotrimeric G-protein. EMBO J 1995; 14:2519–2526.[Medline] [Order article via Infotrieve] Jones ML, Craik JD, Gibbins JM, Poole AW. Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem 2004; 279:40475–40483.[Abstract/Free Full Text] Hua CT, Gamble JR, Vadas MA, Jackson DE. Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1) Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates. J Biol Chem 1998; 273:28332–28340.[Abstract/Free Full Text] Lin SY, Raval S, Zhang Z, et al. The protein-tyrosine phosphatase SHP-1 regulates the phosphorylation of alpha-actinin. J Biol Chem 2004; 279:25755–25764.[Abstract/Free Full Text] Pasquet JM, Quek L, Pasquet S, et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem 2000; 275:28526–28531.[Abstract/Free Full Text] Raugei G, Ramponi G, Chiarugi P. Low molecular weight protein tyrosine phosphatases: small, but smart. Cell Mol Life Sci 2002; 59:941–949.[CrossRef][Medline] [Order article via Infotrieve] Rigacci S, Bucciantini M, Marzocchini R, Berti A. Low molecular weight phosphotyrosine protein phosphatase translocation during cell stimulation with platelet-derived growth factor. FEBS Lett 1998; 432:145–149.[CrossRef][Medline] [Order article via Infotrieve] Rovida E, Rigacci S, Paccagnini A, Dello Sbarba P, Berti A. The low-molecular-weight phosphotyrosine protein phosphatase, when overexpressed, reduces the mitogenic response to macrophage colony-stimulating factor and tyrosine phosphorylation of its receptor. Biochem Biophys Res Commun 1998; 253:300–304.[CrossRef][Medline] [Order article via Infotrieve] Rigacci S, Rovida E, Bagnoli S, Dello Sbarba P, Berti A. Low M(r) phosphotyrosine protein phosphatase activity on fibroblast growth factor receptor is not associated with enzyme translocation. FEBS Lett 1999; 459:191–194.[CrossRef][Medline] [Order article via Infotrieve] Chiarugi P, Cirri P, Marra F, et al. LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signaling. Biochem Biophys Res Commun 1997; 238:676–682.[CrossRef][Medline] [Order article via Infotrieve] Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002; 277:39274–39279.[Abstract/Free Full Text] Chiarugi P, Taddei ML, Cirri P, et al. Low molecular weight protein-tyrosine phosphatase controls the rate and the strength of NIH-3T3 cells adhesion through its phosphorylation on tyrosine 131 or 132. J Biol Chem 2000; 275:37619–37627.[Abstract/Free Full Text] Rigacci S, Rovida E, Dello Sbarba P, Berti A. Low Mr phosphotyrosine protein phosphatase associates and dephosphorylates p125 Focal adhesion kinase, interfering with cell motility and spreading. J Biol Chem 2002; 277:41631–41636.[Abstract/Free Full Text] Rigacci S, Degl'Innocenti D, Bucciantini M, Cirri P, Berti A, Ramponi G. pp60v-src phosphorylates and activates low molecular weight phosphotyrosine-protein phosphatase. J Biol Chem 1996; 271:1278–1281.[Abstract/Free Full Text] Tailor P, Gilman J, Williams S, Couture C, Mustelin T. Regulation of the low molecular weight phosphotyrosine phosphatase by phosphorylation at tyrosines 131 and 132. J Biol Chem 1997; 272:5371–5374.[Abstract/Free Full Text] Chiarugi P, Fiaschi T, Taddei ML, et al. Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation. J Biol Chem 2001; 276:33478–33487.[Abstract/Free Full Text] Ramponi G, Ruggiero M, Raugei G, et al. Overexpression of a synthetic phosphotyrosine protein phosphatase gene inhibits normal and transformed cell growth. Int J Cancer 1992; 51:652–656.[Medline] [Order article via Infotrieve] Marzocchini R, Bucciantini M, Stefani M, et al. Expression, purification and preliminary crystal analysis of the human low Mr phosphotyrosine protein phosphatase isoform 1. FEBS Lett 1998; 426:52–56.[CrossRef][Medline] [Order article via Infotrieve] Rigacci S, Talini D, Berti A. LMW-PTP associates and dephosphorylates STAT5 interacting with its C-terminal domain. Biochem Biophys Res Commun 2003; 312:360–366.[CrossRef][Medline] [Order article via Infotrieve] Canobbio I, Stefanini L, Guidetti GF, Balduini C, Torti M. A new role for FcRIIA in the potentiation of human platelet activation induced by weak stimulation. Cell Signal 2006; 18:861–870.[CrossRef][Medline] [Order article via Infotrieve] Barry FA and Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem 2002; 277:12874–12878.[Abstract/Free Full Text] Torti M, Bertoni A, Canobbio I, Sinigaglia F, Lapetina EG, Balduini C. Rap1B and Rap2B translocation to the platelet cytoskeleton by von Willebrand factor involves FcII receptor-mediated protein tyrosine phosphorylation. J Biol Chem 1999; 274:13690–13697.[Abstract/Free Full Text] Campus F, Lova P, Bertoni A, Sinigaglia F, Balduini C, Torti M. Thrombopoietin complements Gi- but not Gq-dependent pathways for integrin IIbß3 activation and platelet aggregation. J Biol Chem 2005; 280:24386–24395.[Abstract/Free Full Text] Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J Biol Chem 2002; 277:12009–12015.[Abstract/Free Full Text] Huang MM, Indik Z, Brass LF, Hoxie JA, Schreiber AD, Brugge JS. Activation of FcRII induces tyrosine phosphorylation of multiple proteins including FcRII. J Biol Chem 1992; 267:5467–5473.[Abstract/Free Full Text] Anderson GP and Anderson CL. Signal transduction by the platelet Fc receptor. Blood 1990; 6:1165–1172. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor -chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997; 272:23528–23531.[Abstract/Free Full Text] Gibbins J, Asselin J, Farndale R, Barnes M, Law CL, Watson SP. Tyrosine phosphorylation of the Fc receptor -chain in collagen-stimulated platelets. J Biol Chem 1996; 271:18095–18099.[Abstract/Free Full Text] Giannoni E, Raugei G, Chiarugi P, Ramponi G. A novel redox-based switch: LMW-PTP oxidation enhances Grb2 binding and leads to ERK activation. Biochem Biophys Res Commun 2006; 384:376–73. Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost 2001; 86:198–213.[Medline] [Order article via Infotrieve] Chacko GW, Duchemin AM, Coggeshall KM, Osborne JM, Brandt JT, Anderson CL. Clustering of the platelet Fc receptor induces noncovalent association with the tyrosine kinase p72syk. J Biol Chem 1994; 269:32435–32440.[Abstract/Free Full Text] Gratacap MP, Payrastre B, Viala C, Mauco G, Plantavid M, Chap H. Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C2 is an early key event in FRIIA-mediated activation of human platelets. J Biol Chem 1998; 273:24314–24321.[Abstract/Free Full Text] Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (FcRII) on human platelets. Semin Thromb Hemost 1995; 21:1–9.[Medline] [Order article via Infotrieve] Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcRIIA on the platelet plasma membrane. J Biol Chem 1998; 273:5331–5336.[Abstract/Free Full Text] Canobbio I, Bertoni A, Lova P, et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and FcIIA receptor. J Biol Chem 2001; 276:26022–26029.[Abstract/Free Full Text] Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor -chain, Fyn, and Lyn to activate human platelets. Blood 1999; 94:1648–1656.[Abstract/Free Full Text] Liu J, Ware J, Jackson CW, Gartner TK. FcR-chain-dependent IIbß3 elicited outside-in signalling. J Thromb Haemost 2007; 5:426–428.[CrossRef][Medline] [Order article via Infotrieve] Liu J, Ware J, Jackson CW, Gartner TK. FcR-chain signals in the absence of glycoprotein VI. J Thomb Haemost 2007; 5:201–203.[CrossRef] Gibbins JM. The negative regulation of platelet function: extending the role of the ITIM. Trends Cardiovasc Med 2002; 12:213–219.[CrossRef][Medline] [Order article via Infotrieve] Newman PJ and Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 2003; 23:953–964.[Abstract/Free Full Text] Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol 2005; 17:290–297.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Trifiro, S. A. Williams, Y. Cheli, K. Furihata, F. M. Pulcinelli, D. J. Nugent, and T. J. Kunicki The low-frequency isoform of platelet glycoprotein VIb attenuates ligand-mediated signal transduction but not receptor expression or ligand binding Blood, August 27, 2009; 114(9): 1893 - 1899. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-03-081414v1 110/6/1871    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mancini, F. Articles by Torti, M. Search for Related Content PubMed PubMed Citation Articles by Mancini, F. Articles by Torti, M. Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020